Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

NCT01756456 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurotrophic Keratitis
Keratitis
Corneal Ulcer

Interventions

DRUG: rhNGF 10 μg/ml
DRUG: rhNGF 20 μg/ml
OTHER: vehicle

Sponsor

Dompé Farmaceutici S.p.A